J&J CEO Duato sells $12.5M in company stock
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowJ&J CEO Joaquin Duato sold $12.5 million worth of Johnson & Johnson (JNJ) stock. This transaction involved approximately 140,000 shares at an average price of about $89.14 per share. The sale represents a significant divestiture and has raised questions regarding executive confidence in the company's future. Such large insider sales can influence market perceptions and investor sentiment, potentially affecting Johnson & Johnson's stock price in the near term.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Johnson & Johnson (JNJ)
Johnson & Johnson is a healthcare giant spanning pharmaceuticals and medical devices, known for its deep drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier JNJ news
- State Street Healthcare ETFs XLV and XBI: Cost, Performance Comparison
- Johnson & Johnson (JNJ) Offers 2% Yield, Projects 8.2% Earnings Growth
- XLV vs PBE: Comparing Two Healthcare ETFs for Investors
- Coca-Cola (KO) and Johnson & Johnson Big Premarket Moves
- Johnson & Johnson (JNJ) Settles Talc Lawsuits for $5.5 Billion
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
